Abstract
Carotid baroreflex activation has been demonstrated to provide enduring reductions in arterial blood pressure. The aim of this study was to investigate the effect of long-term therapy on renal function. A total of 322 patients were enrolled in the Rheos Pivotal Trial. Group 1 consisted of 236 patients who started baroreflex activation therapy 1 month after device implantation, whereas in the 86 patients from group 2 the device was activated 6 months later. Serum creatinine and urine albumin/creatinine ratio were collected at screening (before device activation), and at months 6 and 12. Multilevel statistical analyses were adjusted for various covariables. Serum creatinine increased from 78 to 84 mu mol/L, and glomerular filtration rate decreased from 92 to 87 mL/min per 1.73 m(2) in group 1 at month 6 (P
Original language | English |
---|---|
Pages (from-to) | 1334-U425 |
Journal | Hypertension |
Volume | 61 |
Issue number | 6 |
DOIs | |
Publication status | Published - Jun 2013 |
Keywords
- albumin/creatinine ratio
- carotid baroreflex activation
- drug-resistant hypertension
- glomerular filtration rate
- renal function